AYVAKIT (avapritinib)

AYVAKIT (avapritinib)

SELF-ADMINISTRATION

Indications for Prior Authorization:

• Indicated for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations

Patients must meet the following criteria for the indication(s) above:

• 18 years of age or older, AND
• Prescribed by an oncologist, AND
• Patient has a diagnosis of unresectable or metastatic GIST, AND
• Patient has a PDGFRA exon 18 mutation, including PDGFRA D842V mutations, as confirmed by chart note documentation, AND
• Patient has tried and failed Imatinib, AND
• Coadministration of Ayvakit™ with strong and moderate CYP3A inhibitors or inducers should be avoided

Dosing:

• 300 mg orally once daily until disease progression or unacceptable toxicity
• If concomitant use with a moderate CYP3A inhibitor cannot be avoided, reduce the starting dose of Ayvakit™ from 300 mg orally once daily to 100 mg orally once daily

Approval:

• 1 year